| Basics |
| Company: |
Eagle Pharmaceuticals, Inc. |
| IPO Date: |
February 12, 2014 |
| Sector: |
Healthcare |
| Industry: |
Drug Manufacturers |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$1.01 | 7.16%
|
| Avg Daily Range (30 D): |
$0.21 | 35.72%
|
| Avg Daily Range (90 D): |
$0.17 | 166.61%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.18M |
| Avg Daily Volume (30 D): |
.01M |
| Avg Daily Volume (90 D): |
.02M |
| Trade Size |
| Avg Trade Size (Sh.): |
80 |
| Avg Trade Size (Sh.) (30 D): |
611 |
| Avg Trade Size (Sh.) (90 D): |
837 |
| Institutional Trades |
| Total Inst.Trades: |
2,334 |
| Avg Inst. Trade: |
$1.51M |
| Avg Inst. Trade (30 D): |
$1M |
| Avg Inst. Trade (90 D): |
$1M |
| Avg Inst. Trade Volume: |
.03M |
| Avg Inst. Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$1.5M |
| Avg Closing Trade (30 D): |
$.76M |
| Avg Closing Trade (90 D): |
$.76M |
| Avg Closing Volume: |
31.51K |
|
|
|
|
| News |
Oct 14, 2024 @ 10:13 PM
Snowflake, Eagle Pharmaceuticals, Blue Ridge Banks...
Source: Johnson Fistel, Llp
|
Oct 10, 2024 @ 5:00 PM
Global Antiemetics Drugs Market to Exhibit Growth ...
Source: Delveinsight
|
May 22, 2024 @ 1:00 PM
Eagle Pharmaceuticals Announces Receipt of Delisti...
Source: Eagle Pharmaceuticals, Inc.
|
Apr 12, 2024 @ 8:05 PM
Eagle Pharmaceuticals Announces Receipt of Notific...
Source: Eagle Pharmaceuticals, Inc.
|
Jan 18, 2024 @ 11:50 AM
Eagle Pharmaceuticals Provides Update on Bendamust...
Source: Eagle Pharmaceuticals, Inc.
|
| Financials |
| |
TTM |
Q2 2023 |
Q1 2023 |
|
Basic EPS
|
$.92
|
$.39
|
$.44
|
|
Diluted EPS
|
$.91
|
$.39
|
$.44
|
|
Revenue
|
$ 257.55M
|
$ 64.65M
|
$ 66.31M
|
|
Gross Profit
|
$ 184.28M
|
$ 47.79M
|
$ 49.01M
|
|
Net Income / Loss
|
$ 11.95M
|
$ 5.16M
|
$ 5.75M
|
|
Operating Income / Loss
|
$ 41.01M
|
$ 10.3M
|
$ 11.77M
|
|
Cost of Revenue
|
$ 73.27M
|
$ 16.86M
|
$ 17.3M
|
|
Net Cash Flow
|
$ -21.21M
|
$ -6.54M
|
$ -33.42M
|
|
PE Ratio
|
1.64
|
|
|
|
